Fulgent Genetics (NASDAQ:FLGT) Issues FY 2026 Earnings Guidance

Fulgent Genetics (NASDAQ:FLGT) updated its FY 2026 earnings guidance on Thursday morning. The company provided EPS guidance of -2.350–2.220 for the period, compared to the consensus EPS estimate of -1.820. The company issued revenue guidance of $330.0 million-$340.0 million, compared to the consensus revenue estimate of $351.2 million.

Analysts Set New Price Targets

FLGT has been the topic of several research reports. Piper Sandler reaffirmed a “neutral” rating and issued a $15.00 target price (down from $30.00) on shares of Fulgent Genetics in a report on Tuesday, May 5th. Weiss Ratings restated a “sell (e+)” rating on shares of Fulgent Genetics in a report on Monday, July 6th. Finally, Wall Street Zen raised shares of Fulgent Genetics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 30th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Fulgent Genetics has an average rating of “Hold” and an average price target of $27.00.

Fulgent Genetics Price Performance

Shares of Fulgent Genetics stock traded up $0.57 during trading on Thursday, hitting $20.21. The stock had a trading volume of 259,193 shares, compared to its average volume of 221,130. Fulgent Genetics has a 12 month low of $13.46 and a 12 month high of $31.04. The firm’s fifty day simple moving average is $19.32 and its 200-day simple moving average is $19.27. The stock has a market cap of $573.96 million, a PE ratio of -8.46 and a beta of 0.89.

Fulgent Genetics (NASDAQ:FLGT) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.12). Fulgent Genetics had a negative net margin of 23.04% and a negative return on equity of 3.24%. The firm had revenue of $85.39 million for the quarter, compared to the consensus estimate of $94.00 million. Fulgent Genetics has set its FY 2026 guidance at -2.350–2.220 EPS. Analysts expect that Fulgent Genetics will post -2.81 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, COO Jian Xie sold 2,146 shares of the company’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $17.89, for a total transaction of $38,391.94. Following the transaction, the chief operating officer owned 367,605 shares of the company’s stock, valued at approximately $6,576,453.45. This represents a 0.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Hanlin Gao sold 1,688 shares of the business’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $17.89, for a total value of $30,198.32. Following the transaction, the insider owned 990,374 shares of the company’s stock, valued at approximately $17,717,790.86. The trade was a 0.17% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 5,980 shares of company stock worth $106,360. Insiders own 36.18% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Millennium Management LLC grew its position in shares of Fulgent Genetics by 1.8% during the 3rd quarter. Millennium Management LLC now owns 1,468,844 shares of the company’s stock worth $33,196,000 after buying an additional 26,582 shares in the last quarter. Vanguard Group Inc. increased its position in Fulgent Genetics by 1.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,179,254 shares of the company’s stock valued at $26,651,000 after purchasing an additional 13,295 shares during the period. RTW Investments LP bought a new stake in shares of Fulgent Genetics in the 4th quarter valued at about $18,521,000. Geode Capital Management LLC boosted its stake in shares of Fulgent Genetics by 1.3% during the fourth quarter. Geode Capital Management LLC now owns 508,224 shares of the company’s stock valued at $13,353,000 after purchasing an additional 6,553 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in Fulgent Genetics by 12.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 402,802 shares of the company’s stock valued at $10,582,000 after buying an additional 43,521 shares during the period. 48.06% of the stock is currently owned by hedge funds and other institutional investors.

About Fulgent Genetics

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.